274 related articles for article (PubMed ID: 15561678)
21. [Mutations of the gene coding for the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Significance as the disease-specific molecular marker for diagnosis, prognosis and innovative therapy approaches].
Spiekermann K; Hiddemann W; Schnittger S
Dtsch Med Wochenschr; 2005 Apr; 130(16):1020-5. PubMed ID: 15830315
[No Abstract] [Full Text] [Related]
22. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22).
Nanri T; Matsuno N; Kawakita T; Suzushima H; Kawano F; Mitsuya H; Asou N
Leukemia; 2005 Aug; 19(8):1361-6. PubMed ID: 15902284
[TBL] [Abstract][Full Text] [Related]
23. Genetic stability of human embryonic stem cells: A first-step toward the development of potential hESC-based systems for modeling childhood leukemia.
Catalina P; Bueno C; Montes R; Nieto A; Ligero G; Sanchez L; Jara M; Rasillo A; Orfao A; Cigudosa J; Hovatta O; Greaves M; Menendez P
Leuk Res; 2009 Jul; 33(7):980-90. PubMed ID: 18930318
[TBL] [Abstract][Full Text] [Related]
24. Expression of the flt3 receptor and its ligand on hematopoietic cells.
Brasel K; Escobar S; Anderberg R; de Vries P; Gruss HJ; Lyman SD
Leukemia; 1995 Jul; 9(7):1212-8. PubMed ID: 7630197
[TBL] [Abstract][Full Text] [Related]
25. Modeling first-hit functions of the t(12;21) TEL-AML1 translocation in mice.
Tsuzuki S; Seto M; Greaves M; Enver T
Proc Natl Acad Sci U S A; 2004 Jun; 101(22):8443-8. PubMed ID: 15155899
[TBL] [Abstract][Full Text] [Related]
26. The expression of FMS, KIT and FLT3 in hematopoietic malignancies.
Birg F; Rosnet O; Carbuccia N; Birnbaum D
Leuk Lymphoma; 1994 Apr; 13(3-4):223-7. PubMed ID: 7519507
[TBL] [Abstract][Full Text] [Related]
27. Normal and oncogenic FLT3.
Naoe T; Kiyoi H
Cell Mol Life Sci; 2004 Dec; 61(23):2932-8. PubMed ID: 15583855
[TBL] [Abstract][Full Text] [Related]
28. Inverse correlation between Flt3 and PU.1 expression in acute myeloblastic leukemias.
Inomata M; Takahashi S; Harigae H; Kameoka J; Kaku M; Sasaki T
Leuk Res; 2006 Jun; 30(6):659-64. PubMed ID: 16271760
[TBL] [Abstract][Full Text] [Related]
29. Discrimination of target by siRNA: designing of AML1-MTG8 fusion mRNA-specific siRNA sequences.
Kasashima K; Sakota E; Kozu T
Biochimie; 2004; 86(9-10):713-21. PubMed ID: 15556282
[TBL] [Abstract][Full Text] [Related]
30. Differential expression of specific microRNA and their targets in acute myeloid leukemia.
Cammarata G; Augugliaro L; Salemi D; Agueli C; La Rosa M; Dagnino L; Civiletto G; Messana F; Marfia A; Bica MG; Cascio L; Floridia PM; Mineo AM; Russo M; Fabbiano F; Santoro A
Am J Hematol; 2010 May; 85(5):331-9. PubMed ID: 20425795
[TBL] [Abstract][Full Text] [Related]
31. [THE CLINICAL SIGNIFICANCE OF GENETIC MUTATIONS IN ACUTE MYELOID LEUKEMIA].
Goryainova NV
Lik Sprava; 2014 Dec; (12):10-8. PubMed ID: 26638462
[TBL] [Abstract][Full Text] [Related]
32. AML1/RUNX1 mutations are infrequent, but related to AML-M0, acquired trisomy 21, and leukemic transformation in pediatric hematologic malignancies.
Taketani T; Taki T; Takita J; Tsuchida M; Hanada R; Hongo T; Kaneko T; Manabe A; Ida K; Hayashi Y
Genes Chromosomes Cancer; 2003 Sep; 38(1):1-7. PubMed ID: 12874780
[TBL] [Abstract][Full Text] [Related]
33. Analysis of class I and II aberrations in Iraqi childhood acute myeloid leukemia using filter paper cards.
Al-Kzayer LF; Uyen le TN; Al-Jadiry MF; Al-Hadad SA; Al-Badri SA; Ghali HH; Ameen NA; Liu T; Matsuda K; Abdulkadhim JM; Al-Shujairi TA; Matti ZI; Hasan JG; Al-Abdullah HM; Al-Ani MH; Saber PA; Khalil HM; Inoshita T; Kamata M; Koike K; Sakashita K
Ann Hematol; 2014 Jun; 93(6):949-55. PubMed ID: 24464319
[TBL] [Abstract][Full Text] [Related]
34. Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease.
Chao MP; Gentles AJ; Chatterjee S; Lan F; Reinisch A; Corces MR; Xavy S; Shen J; Haag D; Chanda S; Sinha R; Morganti RM; Nishimura T; Ameen M; Wu H; Wernig M; Wu JC; Majeti R
Cell Stem Cell; 2017 Mar; 20(3):329-344.e7. PubMed ID: 28089908
[TBL] [Abstract][Full Text] [Related]
35. Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis.
Pronier E; Bowman RL; Ahn J; Glass J; Kandoth C; Merlinsky TR; Whitfield JT; Durham BH; Gruet A; Hanasoge Somasundara AV; Rampal R; Melnick A; Koche RP; Taylor BS; Levine RL
Blood; 2018 Sep; 132(12):1265-1278. PubMed ID: 30064973
[TBL] [Abstract][Full Text] [Related]
36. Driving Toward Precision Medicine for Acute Leukemias: Are We There Yet?
Chung C; Ma H
Pharmacotherapy; 2017 Sep; 37(9):1052-1072. PubMed ID: 28654205
[TBL] [Abstract][Full Text] [Related]
37. Direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells.
Warner JK; Wang JC; Takenaka K; Doulatov S; McKenzie JL; Harrington L; Dick JE
Leukemia; 2005 Oct; 19(10):1794-805. PubMed ID: 16094415
[TBL] [Abstract][Full Text] [Related]
38. Molecularly targeted therapies for pediatric acute myeloid leukemia: progress to date.
Brown P; Smith FO
Paediatr Drugs; 2008; 10(2):85-92. PubMed ID: 18345718
[TBL] [Abstract][Full Text] [Related]
39. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia.
Krivtsov AV; Evans K; Gadrey JY; Eschle BK; Hatton C; Uckelmann HJ; Ross KN; Perner F; Olsen SN; Pritchard T; McDermott L; Jones CD; Jing D; Braytee A; Chacon D; Earley E; McKeever BM; Claremon D; Gifford AJ; Lee HJ; Teicher BA; Pimanda JE; Beck D; Perry JA; Smith MA; McGeehan GM; Lock RB; Armstrong SA
Cancer Cell; 2019 Dec; 36(6):660-673.e11. PubMed ID: 31821784
[TBL] [Abstract][Full Text] [Related]
40. SHP2 inhibition reduces leukemogenesis in models of combined genetic and epigenetic mutations.
Pandey R; Ramdas B; Wan C; Sandusky G; Mohseni M; Zhang C; Kapur R
J Clin Invest; 2019 Dec; 129(12):5468-5473. PubMed ID: 31682240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
